BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 12, 2002
View Archived Issues
United Therapeutics Receives Remodulin Approvable Letter
Following receipt of an approvable letter from the FDA, United Therapeutics Corp. said its orphan drug for pulmonary arterial hypertension should reach the market sometime in the next two months. (BioWorld Today)
Read More
Deltagen Paying $23.5M For BMS Unit, Adding Discovery Capability
Read More
One Of 40 Myosin Proteins In Mammalian Body Led Mice To Key Hearing-Mechanism Clue
Read More
Inhibitex Closing $41M Round To Fund Product Development
Read More
CytRx, Global Genomics Merging In Deal Worth Up To $6.28M
Read More
Other News To Note
Read More
Appointments And Advancements
Read More
U.S. Patent Disclosures
Read More